Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;96(12):e6335.
doi: 10.1097/MD.0000000000006335.

Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis

Ya-Fan Yang  1 , Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang
Affiliations
Review

Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis

Ya-Fan Yang et al. Medicine (Baltimore). 2017 Mar.

Abstract

The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was undertaken to determine the efficacy of cetuximab plus FOLFIRI or FOLFOX.Major databases were searched to identify RCTs investigating wild-type KRAS mCRC after the first-line treatment, and treatment with FOLFOX/FORFIRI ± cetuximab was compared. Data on clinical efficacy and safety were pooled and compared by ORs, HRs, and 95% CIs.Five eligible trials with 1464 patients were included in the meta-analysis. Compared to FOLFOX/FORFIRI, cetuximab as the first-line therapy has improved overall survival (OS) (hazard ratio [HR] = 0.82, 95% confidence interval [CI]: 0.72-0.93, P = 0.003), progression-free survival (PFS) (HR = 0.66, 95% CI: 0.56 -0.77, P < 0.00001), and overall response rate (ORR) (odds ratio [OR] = 2.12, 95% CI: 1.70-2.65, P < 0.00001). However, Grade 3/4 AE was increased with the OR of 2.76 (95%CI: 2.01-3.78, P < 0.00001). The most common grade 3/4 toxicity in the wild-type KRAS population was neutropenia and diarrhea. For cetuximab plus FOLFIRI, there was a higher incidence of grade 3 or 4 diarrhea (OR = 1.76, 95% CI: 1.15-2.70, P = 0.01), but there was no significant difference for neutropenia (OR = 1.35, 95% CI: 1.00-1.83, P = 0.05).The addition of cetuximab in mCRC as the first-line treatment is a potential effective approach in the improved outcomes but associated with increased toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of selection.
Figure 2
Figure 2
Forest plot for OS. Meta-analysis of overall survival associated with cetuximab plus FOLFIRI or FOLFOX versus FOLFIRI or FOLFOX alone in the fixed-effects model. OS = overall survival.
Figure 3
Figure 3
Forest plot for PFS. Meta-analysis of progression-free survival between cetuximab plus FOLFIRI or FOLFOX and FOLFIRI or FOLFOX alone. PFS = progression-free survival.
Figure 4
Figure 4
Forest plot for ORR. Meta-analysis of overall response rate associated with cetuximab plus FOLFIRI or FOLFOX versus FOLFIRI or FOLFOX alone in the fixed-effects model. ORR = overall response rate.
Figure 5
Figure 5
Forest plot for Grade 3/4 toxicity. Meta-analysis of Grade 3/4 toxicity on cetuximab plus FOLFIRI or FOLFOX versus FOLFIRI or FOLFOX alone.
Figure 6
Figure 6
Funnel plot for the publication bias tests. (A) Funnel plot for the HR of OS; (B) funnel plot for the HR of FPS; (C) funnel plot for the OR of ORR. Each point represents a separate study for the indicated association. HR = hazard ratio, ORR = overall response rate, OS = overall survival, FPS = progression-free survival.
See this image and copyright information in PMC

References

    1. Huang J, Nair SG, Mahoney MR, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 2014;13:100–9. - PMC - PubMed
    1. Lyseng-Williamson KA. Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. Mol Diagn Ther 2012;16:317–22. - PubMed
    1. Ooki A, Ando M, Sakamoto J, et al. A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. Jpn J Clin Oncol 2014;44:383–7. - PubMed
    1. Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20:4208–19. - PMC - PubMed
    1. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4 +/− cetuximab as 1st-line treatment for metastatic colorectal cancer: the OPUS study. EJC Suppl 2009;7:346–1346.

MeSH terms

Supplementary concepts